Inhibition of protein kinase B suppresses IKBKE's oncogenic transformation
 

Publishing in the current issue of The Journal of Biological Chemistry (Vol. 286, No 43), researchers at Moffitt Cancer Center in Tampa, Fla., have discovered additional mechanisms of "Akt" activation and suggest a component of that activation mechanism - inhibitor of nuclear factor kappa-B kinase subunit epsilon (IKBKE) - could be targeted as a therapeutic intervention for treating cancer.

More...